NewGenIVF Introduces NewGenSort to Support Men’s Reproductive Health Across Asia
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Tikvah Management LLC, owning 1.5% of Quanterix Corp (QTRX) shares, has announced its intention to vote against the proposed merger with Akoya Biosciences (AKYA) at the upcoming Special Meeting. As a significant investor since 2018, Tikvah argues that the merger undervalues Quanterix shares and would significantly reduce the company's cash runway post-merger. The investment firm also supports other investors' opposition, emphasizing that Quanterix's business is superior to Akoya's. Tikvah maintains the right to modify its position if significant developments arise.
Tikvah Management LLC, che possiede l'1,5% delle azioni di Quanterix Corp (QTRX), ha annunciato la sua intenzione di votare contro la fusione proposta con Akoya Biosciences (AKYA) durante la prossima Assemblea Straordinaria. In qualità di investitore significativo dal 2018, Tikvah sostiene che la fusione sottovaluti le azioni di Quanterix e ridurrebbe notevolmente la liquidità disponibile dell'azienda dopo la fusione. La società di investimenti appoggia inoltre l'opposizione di altri investitori, sottolineando che l'attività di Quanterix è superiore a quella di Akoya. Tikvah si riserva il diritto di modificare la propria posizione qualora emergano sviluppi rilevanti.
Tikvah Management LLC, que posee el 1.5% de las acciones de Quanterix Corp (QTRX), ha anunciado su intención de votar en contra de la fusión propuesta con Akoya Biosciences (AKYA) en la próxima Junta Especial. Como inversor importante desde 2018, Tikvah argumenta que la fusión infravalora las acciones de Quanterix y reduciría significativamente la liquidez de la compañía después de la fusión. La firma de inversión también apoya la oposición de otros inversores, enfatizando que el negocio de Quanterix es superior al de Akoya. Tikvah se reserva el derecho de modificar su posición si surgen desarrollos importantes.
Tikvah Management LLC는 Quanterix Corp(QTRX)의 1.5% 지분을 보유하고 있으며, 다가오는 특별 총회에서 Akoya Biosciences(AKYA)와의 제안된 합병에 반대하는 투표를 할 것이라고 발표했습니다. 2018년부터 주요 투자자로서 Tikvah는 이번 합병이 Quanterix 주식을 저평가하고 합병 후 회사의 현금 운용 기간을 크게 단축시킬 것이라고 주장합니다. 이 투자 회사는 또한 다른 투자자들의 반대 의견을 지지하며, Quanterix의 사업이 Akoya보다 우수하다고 강조합니다. Tikvah는 중요한 상황 변화가 있을 경우 입장을 변경할 권리를 보유하고 있습니다.
Tikvah Management LLC, détenant 1,5 % des actions de Quanterix Corp (QTRX), a annoncé son intention de voter contre la fusion proposée avec Akoya Biosciences (AKYA) lors de la prochaine assemblée spéciale. En tant qu'investisseur important depuis 2018, Tikvah soutient que la fusion sous-évalue les actions de Quanterix et réduirait considérablement la trésorerie disponible de l'entreprise après la fusion. La société d'investissement appuie également l'opposition d'autres investisseurs, en soulignant que l'activité de Quanterix est supérieure à celle d'Akoya. Tikvah se réserve le droit de modifier sa position en cas de développements significatifs.
Tikvah Management LLC, die 1,5 % der Anteile an Quanterix Corp (QTRX) besitzt, hat ihre Absicht bekannt gegeben, gegen die vorgeschlagene Fusion mit Akoya Biosciences (AKYA) bei der bevorstehenden Sonderversammlung zu stimmen. Als bedeutender Investor seit 2018 argumentiert Tikvah, dass die Fusion die Quanterix-Aktien unterbewertet und die finanzielle Handlungsfähigkeit des Unternehmens nach der Fusion erheblich einschränkt. Die Investmentfirma unterstützt außerdem den Widerstand anderer Investoren und betont, dass das Geschäft von Quanterix dem von Akoya überlegen ist. Tikvah behält sich das Recht vor, seine Position bei wesentlichen Entwicklungen zu ändern.
Positive
- Quanterix's business is considered superior to Akoya's
- Significant shareholders actively engaging in protecting shareholder value
- Company maintains flexibility to consider better strategic alternatives
Negative
- Proposed merger could potentially undervalue Quanterix shares
- Merger would significantly reduce company's cash runway
- Growing shareholder opposition could create uncertainty about the company's strategic direction
Tikvah reserves the right to change this intention should there be significant new developments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324019163/en/
Media Contact:
Josh Kuckley
980 433 1057
jk@simcah.com
Source: Tikvah Management LLC
FAQ
Why is Tikvah Management voting against the Quanterix-Akoya merger?
Tikvah Management is voting against the merger because they believe it undervalues Quanterix shares, would reduce the company's cash runway post-merger, and considers Quanterix's business superior to Akoya's.
What percentage of Quanterix (QTRX) shares does Tikvah Management own?
Tikvah Management owns approximately 1.5% of Quanterix's outstanding common shares.
What are the main concerns about the Quanterix-Akoya merger in 2025?
The main concerns include undervaluation of Quanterix shares, significant reduction in cash runway post-merger, and the belief that Quanterix's business is superior to Akoya's.
Can Tikvah Management change its voting decision on the QTRX-AKYA merger?
Yes, Tikvah Management has reserved the right to change its voting intention if there are significant new developments.
Akoya Biosciences, Inc.
NASDAQ:AKYA
AKYA Rankings
AKYA Latest News
AKYA Stock Data
60.35M
25.63M
67.21%
69.85%
7.27%
Medical Instruments & Supplies
Laboratory Analytical Instruments
United States
MARLBOROUGH